Furiex Pharmaceuticals, Inc. Stockholders Encouraged to Contact Securities Law Firm about Takeover

News provided by

Apr 28, 2014, 04:15 ET

DALLAS, April 28, 2014 /PRNewswire/ -- Securities lawyers at Deans & Lyons announce an investigation of the board of Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) in connection with a buyout for $95 per share. Concerned FURX investors are encouraged to contact attorney Hamilton Lindley by clicking here.

"Since at least one analyst set the target price at $140 per share and its was trading above $95 as recently as February 5, 2014, this potential investigation concerns whether the shareholders are receiving the highest price reasonably available for their stock," said securities lawyer Hamilton Lindley. "Our potential shareholder lawsuit will seek to ensure that all relevant information is disclosed and that the Furiex Pharmaceuticals, Inc. shareholders receive the highest price reasonably available for their stock."

Deans & Lyons has significant experience representing shareholders in securities lawsuits nationwide. FURX stockholders – or anyone with knowledge about this situation – should contact lawyer Hamilton Lindley at [email protected] with questions or concerns or visit http://www.deanslyons.com/News/FURX.shtml.

Hamilton Lindley

DEANS & LYONS LLP

325 North Saint Paul Street, Suite 1500
Dallas, TX 75201
Phone: 214-736-7861
Fax: 214-965-8505
Toll-free: 877-819-8033

[email protected]

www.deanslyons.com

SOURCE Deans & Lyons LLP